Key result
Subcutaneous treprostinil increased walking distance by a mean of 114 m at 12 months in adults with congenital heart disease-related pulmonary arterial hypertension.
Why the study?
Does subcutaneous treprostinil improve exercise capacity and hemodynamics in adult patients with congenital heart disease-associated pulmonary arterial hypertension?
Observational (n=32)
Does subcutaneous treprostinil improve exercise capacity and hemodynamics in adult patients with congenital heart disease-associated pulmonary arterial hypertension?
Answers are grounded in this paper and cite their sources.
Subcutaneous treprostinil is generally safe and significantly improves 6-minute walk distance, WHO functional class, and hemodynamics in adults with advanced congenital heart disease-associated PAH.
OBJECTIVE: To assess the efficacy and safety of subcutaneous treprostinil in adult patients with congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH) after 12 months of treatment. METHODS: Consecutive adult patients with CHD-PAH received subcutaneous treprostinil to maximum tolerated doses in an observational study. RESULTS: Advanced CHD-PAH patients with WHO class III or IV disease (n=32, age 40±10 years, 20 females) received treprostinil for suboptimal response to bosentan (n=12), WHO functional class IV disease (FC, n=7) or prior to bosentan approval (n=13). In the multivariate mixed model, mean increase in 6 min walk distance (6-MWD) from baseline to 12 months was 114 m (76; 152) (P<0.001). WHO FC improved significantly (P=0.001) and B-type brain natriuretic peptide decreased from 1259 (375; 2368) pg/mL to 380 (144; 1468) pg/mL (P=0.02). In those 14 patients who had haemodynamic data before and after initiation of treprostinil, pulmonary vascular resistance decreased significantly (from 18.4±11.1 to 12.6±7.9 Wood units, P=0.003). The most common adverse events were infusion-site erythema and pain. One patient stopped treatment because of intolerable infusion-site pain after 8 months of treatment. No other major treatment-related complications were observed. Five patients died during early follow-up, having experienced a decrease in their 6-MWD prior. CONCLUSIONS: Subcutaneous treprostinil therapy is generally safe and effective for at least 12 months and may be used in CHD-related PAH class III and IV.
No takes yet. Share an insight, caveat, or question.
Skoro‐Sajer et al. (2018) conducted an observational in congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH) (n=32). Subcutaneous treprostinil was evaluated on Change in 6 min walk distance (6-MWD) from baseline to 12 months (MD 114, 95% CI 76-152, p=<0.001). Subcutaneous treprostinil increased walking distance by a mean of 114 m at 12 months in adults with congenital heart disease-related pulmonary arterial hypertension.
Synapse has enriched 10 related papers. Consider them for comparative context: